GGrantIndex
← Leaderboards

Aliasger K Salem

University Of Iowa

$2,971,479
Attributed
$5,344,929
Total exposure
9
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $690.5K · FY200825
$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$5,344,929 · 9

By mechanism

U01$2,652,788 · 1
R21$1,876,125 · 5
R01$588,731 · 1
P30$227,285 · 2

Top collaborators

Most similar at University Of Iowa

Same institution · by research overlap

Others in their field

Top investigators on “Nanoparticle

Research focus

NanoparticleBaseResponseModalityInnovationSolid NeoplasmCancer ImmunotherapyPeer ReviewMalignant NeoplasmsLeadCellsDesignImmunizationEvaluationClinical TrialsIn SituNanoMultidisciplinaryNovel TherapeuticsMultiple MyelomaProgramsNovel StrategiesCollegeInvestigational Therapies

Grant awards (28)

Modulating Ferroptosis in Fuchs Endothelial Corneal Dystrophy$588,731
R01 · FY2025 · EY
Cationic CAMKIIN nanoparticles that reduce chlorine-induced airway oxidative stress$231,750
R21 · FY2023 · ES · contact PI
CST6-mRNA activated matrices for efficient bone regeneration$231,750
R21 · FY2023 · DE · contact PI
Optimizing Rho-associated kinase inhibitors for use in treating Fuchs endothelial corneal dystrophy$193,125
R21 · FY2023 · EY
Experimental Therapeutics$33,883
P30 · FY2023 · CA · contact PI
Optimizing Rho-associated kinase inhibitors for use in treating Fuchs endothelial corneal dystrophy$231,750
R21 · FY2022 · EY
Cationic CAMKIIN nanoparticles that reduce chlorine-induced airway oxidative stress$193,125
R21 · FY2022 · ES · contact PI
CST6-mRNA activated matrices for efficient bone regeneration$193,125
R21 · FY2022 · DE · contact PI
Experimental Therapeutics$33,883
P30 · FY2022 · CA · contact PI
Nanovaccine platforms to combat pancreatic cancer$507,337
U01 · FY2021 · CA
Nanovaccine platforms to combat pancreatic cancer$506,063
U01 · FY2020 · CA
Program 2: Experimental Therapeutics$27,356
P30 · FY2020 · CA · contact PI
Nanovaccine platforms to combat pancreatic cancer$529,150
U01 · FY2019 · CA
Program 2: Experimental Therapeutics$27,356
P30 · FY2019 · CA · contact PI
Nanovaccine platforms to combat pancreatic cancer$543,977
U01 · FY2018 · CA
Program 2: Experimental Therapeutics$27,356
P30 · FY2018 · CA · contact PI
Program 2: Experimental Therapeutics$7,201
P30 · FY2018 · CA · contact PI
Program 2: Experimental Therapeutics$6,879
P30 · FY2018 · CA · contact PI
Program 2: Experimental Therapeutics$4,902
P30 · FY2018 · CA · contact PI
Program 2: Experimental Therapeutics$3,645
P30 · FY2018 · CA · contact PI
Program 2: Experimental Therapeutics$1,699
P30 · FY2018 · CA · contact PI
Nanovaccine platforms to combat pancreatic cancer$566,261
U01 · FY2017 · CA
Program 2: Experimental Therapeutics$23,461
P30 · FY2017 · CA · contact PI
Program 2: Experimental Therapeutics$29,664
P30 · FY2016 · CA · contact PI
Engineered Optimal Adjuvant and Antigen Release from Biodegradable Nanoparticles$132,000
R21 · FY2010 · CA · contact PI
Chitosan-plasmid DNA nanoplexes and adenoviruses as prostate cancer vaccines$168,750
R21 · FY2009 · CA · contact PI
Engineered Optimal Adjuvant and Antigen Release from Biodegradable Nanoparticles$132,000
R21 · FY2009 · CA · contact PI
Chitosan-plasmid DNA nanoplexes and adenoviruses as prostate cancer vaccines$168,750
R21 · FY2008 · CA · contact PI